References
- Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict. Sci. Clin. Pract.4, 4–16 (2007).
- Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict.16, 331–342 (2007).
- Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet369, 1047–1053 (2007).
- Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs23, 543–553 (2009).
- Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int. Rev. Psychiatry21, 104–112 (2009).
- Mechoulam R. Marihuana chemistry. Science168, 1159–1163 (1970).
- Devane WA, Dysarz FA, Johnson MR et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol.34, 605–613 (1988).
- Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today42, 495–501 (2006).
- Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of delta-9-THC and cannabidiol on nocturnal sleep and early morning behaviour in young adults. J. Clin. Psychopharmacol.24, 305–313 (2004).
- Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol.15(Suppl. 3), 365 (2008).
- Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex® in patients with multiple sclerosis. Mult. Scler.12, S111 (2006).
- Sativex® integrated safety analysis, 2007. Data on file, GW Pharma.
- Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler.12, 639–645 (2006).
- Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler.13, S129 (2007).
- Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who were receiving long term Sativex® (nabiximols). Mult. Scler.18(2), 219–228 (2011).
- Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol.18, 1122–1131 (2011).
- Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res.32, 451–459 (2010).
- Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin. Drug Saf.10, 675–685 (2011).
- Aragona M, Onesti E, Tomassini V et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol.32, 41–47 (2009).
- Schoedel K, Chen N, Hilliard A et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum. Psychopharmacol. doi:10.1002/hup.1196 (2011) (Epub ahead of print).
- Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
- Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Syst. Rev.2, CD001332 (2004).
- Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res.11, 205–213 (2011).